GWS
CPRX icon

Glassman Wealth Services’s Catalyst Pharmaceutical CPRX Stock Holding History

Glassman Wealth Services’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-11,340
Closed -$38K – 1425
2020
Q4 		$38K Hold
11,340
– – 0.01% 380
2020
Q3 		$34K Hold
11,340
– – 0.01% 352
2020
Q2 		$52K Hold
11,340
– – 0.02% 247
2020
Q1 		$44K Hold
11,340
– – 0.02% 243
2019
Q4 		$43K Hold
11,340
– – 0.02% 277
2019
Q3 		$60K Sell
11,340
-1,960
-15% -$10.4K 0.02% 213
2019
Q2 		$51K Buy
13,300
+1,000
+8% +$4.32K 0.02% 233
2019
Q1 		$63K Hold
12,300
– – 0.03% 208
2018
Q4 		$24K Buy
+12,300
New +$35.2K 0.01% 270

Other funds holding CPRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Glassman Wealth Services's CPRX Position: Q1 2021 in Review

Glassman Wealth Services sold out of Catalyst Pharmaceutical (CPRX) in Q1 2021, closing a stake of 11,340 shares — an estimated $38K sold.

Glassman Wealth Services first reported a position in CPRX in Q4 2018 and held it in 9 quarters. The position peaked at $63K in Q1 2019. 133 funds tracked by Wall St. Rank hold CPRX as of Q1 2021.

  • Glassman Wealth Services reported no remaining Catalyst Pharmaceutical position as of Q1 2021 after selling out during the quarter.
  • Glassman Wealth Services sold 11,340 Catalyst Pharmaceutical shares in Q1 2021, an estimated $38K.
  • Glassman Wealth Services first reported a position in Catalyst Pharmaceutical in Q4 2018 and held it in 9 quarters.
  • Glassman Wealth Services's Catalyst Pharmaceutical position peaked at $63K in Q1 2019.
  • 133 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2021.

Based on Glassman Wealth Services's 13F filing for Q1 2021, filed 5 May 2021.